Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444437) titled 'LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.
Condition:
Non-Small Cell Lung Cancer
Intervention:
Biological: LM103 TILs Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 26, 2026
Target Sample Size: 45
Countries of Recruitment:
China
To know more, visit https://clinicaltria...